

Klatskin Tumor

Klatskin tumor is malignant cholangiocarcinoma arising from extrahepatic bile duct near the confluence of left and right hepatic ducts. It is hilar carcinoma. ^[1]

Epidemiology and Etiology

Klatskin tumor is quite rare, more in male sex in age > 60 years.^[1] There is proved connection between this malignant tumor and primary sclerosis cholangitis (autoimmune disease) and parasitic infection in biliary ducts (*Clonorchis sinensis* and *Opisthorchis viverrini*, both in Southeast Asia).

Pathology

It is cholangiocarcinoma (usually cylindrocellular adenocarcinoma) in more than 90% of cases, grows slowly, is locally aggressive – can penetrate to portal vein, hepatic artery, liver parenchyma. Metastasise quite late (lymph nodes in porta hepatis, liver).^[1]

 For more information see *Cholangiocarcinoma*.

Clinical Features

Symptomes are very similar to pancreatic head cancer:

- painless obstructive jaundice, possible Courvoisier sign;
- abdominal pain;
- weight loss.^[2]

Diagnostic Methods^[2]

- lab: higher bilirubin, tumormarker **CA 19-9** (but is not specific, can be found in patients with colon cancer, pancreatic cancer or biliary obstruction);
- USG: possible biliary duct dilatation, gallbladder dilatation;
- **EUSG**: through the wall of the stomach or duodenum is possible find the tumor;
- **MRCP**: is preferred more than ERCP, because MRCP is noninvasive methode which can show stage of tumor process;
- ERCP (endoscopic retrograde cholangio-pancreatography) should be preferred only if there is no MRCP examination possible or is necessary therapeutic intervention of biliary obstruction (stent);
- **CT**: computer tomography is always necessary in staging, results of CT will decide about the therapy, should be always performed before ERCP (because we need to have images before intervention)!


Classification

TNM Classification^[3]





- Tis – carcinoma in situ;
- T1 – tumor is in muscular layer of biliar duct;
- T2a – tumor penetrates to lipid tissue;
- T2b – tumor petetrates to liver parenchyma;
- T3 – tumor penetrates to left or right portal vein or left or right hepatic artery;
- T4 – tumor penetrates to portal vein, or left and right portal vein, or common hepatic artery, ...

 For more information see *TNM*.

Bismuth classification



hepatic ducts anatomy



| STAGE | T | N | M |
|-------------------|------------|--------|----|
| Stage 0 | Tis | N0 | M0 |
| Stage I | T1 | N0 | M0 |
| Stage II | T2a, T2b | N0 | M0 |
| Stage IIIa | T3 | N0 | M0 |
| Stage IIIb | T1, T2, T3 | N1 | M0 |
| Stage IVa | T4 | N0, N1 | M0 |
| Stage IVb | T1-T4 | N0, N1 | M1 |

Bismuth Classification

is based on tumor's localization in extrahepatic biliary tree:

- **Bismuth I** – tumor of common hepatic duct, not reaching the junction;
- **Bismuth II** – tumor of common hepatic duct, reaching the junction;
- **Bismuth III** – tumor of common hepatic duct and left or right hepatic duct;
- **Bismuth IV** – tumor of common hepatic duct and left and right hepatic duct.

Therapy

Curative Therapy

Only **radical tumor resection** can be curative and should be performed only in stage I or II of TNM classification. It is extensive surgery with bile duct and right liver lobe (or extend right liver lobe) resection and hepaticojejunostomy (Roux Y-loop).

Palliative Therapy

In nonoperable tumors (TNM stage III and IV) is **chemotherapy** performed. Usually gemcitabine (nucleoside analogue) and cisplatin. Average survival time is 8.5 months.^[4]

Palliative therapy is based on **hepatic ducts patency** (drainage of bile):

- internal drainage – (metallic) stent via ERCP;
- external drainage – PTD (percutaneous transhepatic drainage).

Last but not least is **therapy of pain**.

Links

Related articles

- Pancreatic Cancer
- Cholangiocarcinoma

References

1. POVÝŠIL, Ctibor, et al. *Speciální patologie*. 2. edition. Prague : Galén, 2007. pp. 199. ISBN 978-80-7262-494-2.
2. BURKITT, H. George – QUICK, Clive R. G. *Essential surgery : problems, diagnosis and management*. 4. edition. Edinburgh ; New York : Churchill Livingstone, 2007. 793 pp. pp. 369-373. ISBN 9780443103469.
3. SOBIN, L.H – GOSPODAROWITZ, M.K – WITTEKIND, Ch. *TNM : Classification of Malignant Tumors*. 7. edition. 2009. ISBN 978-80-904259-6-5.
4. ŠMAKAL, Martin. *Komplexní léčení nádorů - role onkologa* [lecture for subject Surgery, specialization Surgery, 1. LF UK Charles University in Prague]. Prague. 2011-10-21.